PAREXEL Commercialization Experts to Present Best-Practice Approaches for Demonstrating Product Value at ISPOR Annual European Congress

BOSTON, Nov. 2, 2011 /PRNewswire/ -- Commercialization experts from PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, will discuss how to maximize product value through launch and over the entire product lifecycle at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 14th Annual European Congress, to be held November 5 – 8, 2011 in Madrid, Spain.  Attendees from biopharmaceutical companies can learn about best-practice approaches to align reimbursement strategies with clinical development to gather the precise data required to demonstrate product value by visiting PAREXEL Stands 53 and 54 in the exhibit hall.

The ISPOR meeting program features numerous sessions, which will be presented by PAREXEL experts, including:

Monday, November 7

Symposium:  Integrated Regulatory and Commercial Planning: Internal Approaches and Value to Payers, 7:00

• Moderator: Richard Morton, Ph.D., Vice President

Poster Presentations Session II, 17:30:

• PHP102:  Biosimilars: Pricing & Reimbursement in Germany, Suchita Chaudhari, Consultant
• PHP109:  Tendering of Biosimilars in the UK, Ivan Viejo Viejo, Consultant
• PHP111:  ISPOR: Awareness, Drivers and Barriers to Involvement of UK Cancer Network Stakeholders, Richard Morton, Ph.D., Vice President
• PHP112:  Inter-Individuality Country Variability in mAbs – Reimbursement and Coverage Following EMA Approval, Carmen Rossi, Consultant and Kimberly Miller, Director

Tuesday, November 8

Poster Presentations Session III, 11:00:

• PCN163:  Funding by SHAS for Rarer Cancers in England, Suchita Chaudhari, Consultant
• PCN 171:  Underlying Causes for Sub-Optimal Utilization of Cancer Drugs Funds in England, Ivan Viejo Viejo, Consultant

PAREXEL provides solutions that deliver effective alignment of development and commercialization strategies as early as possible in the development process.  For more information about commercialization services from PAREXEL visit:  http://www.PAREXEL.com/services-and-capabilities/consulting/reimbursement-market-access/ or Stands 53 and 54 during the meeting.  Information about the ISPOR Annual European Congress can be found at www.ispor.org.

About PAREXEL International

PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries.  Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement.  Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process.  Headquartered near Boston, Massachusetts, PAREXEL operates in 67 locations throughout 52 countries around the world, and has approximately 10,850 employees.  For more information about PAREXEL International visit www.PAREXEL.com.

This release contains "forward-looking" statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand.   For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements.  Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "should,"  "targets," and similar expressions are also intended to identify forward-looking statements.  The forward-looking statements in this release involve a number of risks and uncertainties.  The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release.  Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, including the anticipated additional restructuring charges of approximately $4 million in the second quarter of Fiscal Year 2012; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug,  medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks.   Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2011 as filed with the SEC on August 26, 2011, which "Risk Factors" discussion is incorporated by reference in this press release.  The Company specifically disclaims any obligation to update these forward-looking statements in the future.  These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc.  All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.

SOURCE PAREXEL International Corporation

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED